Carlo Porrozzi
Papers
1
Total Citations
9
H-Index
1
About
Carlo Porrozzi is a dedicated researcher in urologic oncology, with a focused expertise in improving the early detection and risk stratification of prostate cancer. His primary research centers on the clinical utility of novel biomarkers, particularly the Prostate Health Index (PHI) and its derivative, the percentage of p2PSA to free PSA (%p2PSA). Porrozzi’s major contribution lies in demonstrating how these advanced PSA isoforms can more accurately predict aggressive prostate cancer at radical prostatectomy, offering a significant improvement over traditional PSA testing. His landmark 2015 study, cited nine times, provided critical evidence that PHI enhances the preoperative identification of high-risk pathology, helping to reduce unnecessary biopsies and overtreatment of indolent disease. This work has been instrumental in shifting clinical practice toward more precise, biomarker-driven decision-making. Porrozzi’s research continues to impact the field by bridging the gap between serum markers and final pathological outcomes, ultimately aiming to refine patient selection for surgery and improve long-term oncologic outcomes.
Research Focus
Key Achievements
Top Papers
- 1